A meta‐analytic framework to adjust for bias in external control studies
暂无分享,去创建一个
Devin Incerti | Chris Harbron | Michael T Bretscher | Ray Lin | C. Harbron | M. Bretscher | D. Incerti | Ray S. Lin
[1] Geert Molenberghs,et al. Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.
[2] V. Sambucini. Comparison of Single-Arm vs. Randomized Phase II Clinical Trials: A Bayesian Approach , 2015, Journal of biopharmaceutical statistics.
[3] James G. Scott,et al. On the half-cauchy prior for a global scale parameter , 2011, 1104.4937.
[4] C. Gerlinger,et al. The use of external controls: To what extent can it currently be recommended? , 2021, Pharmaceutical statistics.
[5] A. Gelman. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) , 2004 .
[6] D. Rubin,et al. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 1985 .
[7] Peter C Austin,et al. A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003 , 2008, Statistics in medicine.
[8] S. Toh,et al. Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions , 2020, Pharmacoepidemiology and drug safety.
[9] D. Rubin,et al. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .
[10] S. Schneeweiss,et al. Emulating Randomized Clinical Trials with Nonrandomized Real-World Evidence Studies: First Results from the RCT DUPLICATE Initiative. , 2020, Circulation.
[11] Elizabeth A Stuart,et al. Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.
[12] William B. Capra,et al. Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials , 2019, Clinical pharmacology and therapeutics.
[13] D. Rubin. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.
[14] G. Collins,et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance , 2017, BMC Medical Research Methodology.
[15] R. Simon,et al. The role of nonrandomized trials in the evaluation of oncology drugs , 2015, Clinical pharmacology and therapeutics.
[16] D. Rubin. For objective causal inference, design trumps analysis , 2008, 0811.1640.
[17] John K Kruschke,et al. Bayesian data analysis. , 2010, Wiley interdisciplinary reviews. Cognitive science.
[18] M. Schemper,et al. The estimation of average hazard ratios by weighted Cox regression , 2009, Statistics in medicine.
[19] Joshua Haimson,et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research , 2020, ArXiv.
[20] Jay J H Park,et al. Synthetic and External Controls in Clinical Trials – A Primer for Researchers , 2020, Clinical epidemiology.
[21] Frank Bretz,et al. Beyond Randomized Clinical Trials: Use of External Controls , 2019, Clinical pharmacology and therapeutics.
[22] Daniel Farewell,et al. Making apples from oranges: Comparing noncollapsible effect estimators and their standard errors after adjustment for different covariate sets , 2020, Biometrical journal. Biometrische Zeitschrift.
[23] Aki Vehtari,et al. Visualization in Bayesian workflow , 2017, Journal of the Royal Statistical Society: Series A (Statistics in Society).
[24] S. Baxi,et al. Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR , 2020 .
[25] M J Daniels,et al. Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.
[26] Mark Lunt,et al. Avoiding pitfalls when combining multiple imputation and propensity scores , 2019, Statistics in medicine.
[27] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[28] Jasjeet S. Sekhon,et al. Multivariate and Propensity Score Matching Software with Automated Balance Optimization: The Matching Package for R , 2008 .
[29] E. Stuart,et al. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.
[30] Yang Wang,et al. Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis , 2019 .
[31] Gianluca Baio,et al. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014 , 2016, BMJ Open.
[32] P. Austin. American Journal of Epidemiology Practice of Epidemiology Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-one Matching on the Propensity Score , 2022 .
[33] P. Austin. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.
[34] Ulrich Beyer,et al. A multistate model for early decision‐making in oncology , 2018, Biometrical journal. Biometrische Zeitschrift.
[35] M. Hernán,et al. Why Test for Proportional Hazards? , 2020, JAMA.
[36] A. Gajra,et al. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[37] J. Sekhon,et al. Genetic Matching for Estimating Causal Effects: A General Multivariate Matching Method for Achieving Balance in Observational Studies , 2006, Review of Economics and Statistics.
[38] G. Imbens,et al. Large Sample Properties of Matching Estimators for Average Treatment Effects , 2004 .